

Thursday, May 3, 2018

08:30 - 08:45

Opening Address

Room: Confederation I - Level 4

08:45 - 10:15

PL01: Plenary Session 01 - Global Perspective on Trends in Mesothelioma

Track: Epidemiology

Chairs: Jim teWaterNaude, South Africa & Donna Maziak, Canada

Room: Confederation I - Level 4

08:45

PL01.01: Nordic Perspective

Gunnar Hillerdal, Karolinska Hospital, Sweden

09:00

PL01.02: North American Perspective

Paul Demers, Cancer Care Ontario, Canada

09:15

PL01.03: Oceanian Perspective

Matthew Soeberg, The University of Sydney, Australia

09:30

PL01.04: Peripheral Blood DNA Methylation as Potential Biomarker for Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects (Abstract ID: 632)

Giuseppe Matullo, Italian Institute for Genomic medicine and Department of Medical Sciences, Italy

09:40

PL01.05: Malignant Pleural Mesothelioma (MPM): A Surveillance, Epidemiology and End Results (SEER) Database Analysis (Abstract ID: 712)

Hala Aziz, National Cancer Institute, Egypt

09:50

PL01.06: Asbestos Disease Research in Former Soviet Union and Russia: Literature Comparisons with United Kingdom and Japan (Abstract ID: 749)

Oluf Røe, Norwegian University of Science and Technology, Norway

10:00

PL01.07: Childhood School Attendance Near an Asbestos Cement Plant and Adult Mesothelioma Risk (Abstract ID: 800)

Sofie Dalsgaard, Aalborg University, Denmark

10:10

PL01.08: Question & Answer Period



10:15 - 11:00

Poster Viewing with Coffee

Room: Confederation II/III - Level 4

11:00 - 12:30

MS01: Mini Symposium 01 - Patterns of Practice, a Global Perspective

Track: Nursing

Chairs: Rayelle Richard, Canada & Melissa Culligan, United States

Room: Confederation I - Level 4

11:00 **MS01.01: North American Perspective: Highlighting the Role of the Mesothelioma Nurse in a Multidisciplinary Clinic**
 Anastasia Bykova, University Health Network, Canada

11:15 **MS01.02: UK Perspective: Lessons from the UK**
 Liz Darlison, Mesothelioma UK, United Kingdom

11:30 **MS01.03: A South African Perspective**
 Phemelo Magabanyane, Asbestos Relief Trust, South Africa

11:45 **MS01.04: A Nurse's Expertise in the Conduct of Clinical Trials in Mesothelioma**
 Buerkley Rose, University of Chicago, United States

12:00 **MS01.05: Case-Based Discussion (Surgical / Non Surgical)**
 Melissa Culligan, University of Maryland School of Medicine, United States

12:15 **MS01.06: Question & Answer Period**

11:00 - 12:30

MS02: Mini Symposium 02 - Molecular Pathways and Diagnosis in MPM

Track: Pathology

Chairs: Aliya Husain, United States, & Andrew Churg, Canada

Room: Provinces I - Level 4

11:00 **MS02.01: Grading of Mesothelioma**
 Aliya Husain, University of Chicago, United States

11:15 **MS02.02: Live Cell Imaging for the Diagnosis of Malignant Pleural Mesothelioma by Needle-Based Confocal Laser Endomicroscopy (nCLE) (Abstract ID: 832)**
 Paul Baas, Netherlands Cancer Institute, Netherlands

11:25 **MS02.03: MET Amplification Status and Expression in Malignant Mesothelioma (Abstract ID: 788)**
 Eric Santoni-Rugiu, Rigshospitalet, Denmark



- 11:35** **MS02.04: The Role of EZH2 in the Proliferation, Migration, and Tumorigenicity of Malignant Mesothelioma (Abstract ID: 679)**
 Tohru Tsujimura, Hyogo College of Medicine, Japan
- 11:45** **MS02.05: HEG1 is a New Immunohistochemical Marker for the Pathological Diagnosis of Malignant Mesothelioma (Abstract ID: 623)**
 Kenzo Hiroshima, Tokyo Women's Medical University, Japan
- 11:55** **MS02.06: Molecular Pathways and Biomarkers in Diagnosis and Prognosis of MPM**
 Sanja Dacic, Pittsburg University Hospital, United States
- 12:10** **MS02.07: Molecular Subtypes Characterization of Malignant Pleural Mesothelioma and Deconvolution Approach for Prognostic Assessment (Abstract ID: 600)**
 Yuna Blum, Ligue Nationale Contre Le Cancer, France
- 12:20** **MS02.08: Question & Answer Period**

11:00 - 12:30

MS03: Mini Symposium 03 - Imaging

Track: Imaging

Chairs: Ashish Gupta, Canada & Sam Armato, United States

Room: Provinces II - Level 4

- 11:00** **MS03.01: Preclinical Imaging**
 Roslyn Francis, University of Western Australia, Australia
- 11:15** **MS03.02: Dynamic Enhancement of Malignant Pleural Mesothelioma with Computed Tomography (CT): A Prospective Clinical Trial (Abstract ID: 825)**
 Sharyn Katz, University of Pennsylvania Perelman School of Medicine, United States
- 11:25** **MS03.03: Novel Descriptors for Clinical Staging of Malignant Pleural Mesothelioma (Abstract ID: 784)**
 Muzaffer Metintas, Eskisehir Osmangazi University, Turkey
- 11:35** **MS03.04: Novel MRI Methodology for the Assessment of Tumour Volume in MPM (Abstract ID: 619)**
 Kevin Blyth, Queen Elizabeth University Hospital, United Kingdom
- 11:45** **MS03.05: Deep Learning Applied to the Segmentation of Malignant Pleural Mesothelioma Tumor on Computed Tomography Scans (Abstract ID: 655)**
 Eyjolfur Gudmundsson, University of Chicago, United States



- 11:55** **MS03.06: CT Radiomics to Predict Outcome in Patients with Malignant Pleural Mesothelioma (Abstract ID: 741)**
Isabelle Opitz, University Hospital Zürich, Switzerland
- 12:05** **MS03.07: An Update on the Staging System for MPM**
Valerie Rusch, Memorial Sloan Kettering Cancer Center, United States
- 12:20** **MS03.08: Discussant: The Evolving Role of Imaging for Mesothelioma**
Sam Armato, University of Chicago, United States

12:30 - 13:45

Lunch Break

Room: Confederation II/III - Level 4

13:45 - 15:15

MS04: Mini Symposium 04 - Towards Personalized Systemic Therapy

Track: Medical Oncology

Chairs: Anna Nowak, Australia & Oluf Røe, Norway

Room: Confederation I - Level 4

- 13:45** **MS04.01: Novel Targets, New Drugs, and New Combinations**
Dean Fennell, University of Leicester & University Hospitals of Leicester NHS Trust, United Kingdom
- 14:00** **MS04.02: Loss of BAP1 Function Leads to TRAIL Sensitivity in Malignant Mesothelioma (Abstract ID: 759)**
Krishna Kolluri, University College London, United Kingdom
- 14:10** **MS04.03: The Prediction of Resistance to Chemotherapy Using Somatic Copy Number Variation in Mesothelioma (PRiSM) Study: An Update (Abstract ID: 745)**
Kevin Blyth, Queen Elizabeth University Hospital, United Kingdom
- 14:20** **MS04.04: Genomic Mechanisms Underpinning BAP1 Loss in Mesotheliomas from Patients Treated with the EZH2 Inhibitor Tazemetostat (Abstract ID: 647)**
Dean Fennell, University of Leicester & Leicester University Hospitals, United Kingdom
- 14:30** **MS04.05: PARP Inhibitors as Single Agent or with Temozolomide against Primary Mesothelioma Cell Lines with BAP1 Mutations (Abstract ID: 771)**
Daniel Rathkey, National Institutes of Health, United States



14:40 MS04.06: Expression of FGFRs and Evaluation of Efficacy of Different TKIs against FGFR1-4 in MPM (Abstract ID: 790)
 Gregor Vlacic, University Clinic Golnik, Slovenia

14:50 MS04.07: Discussant
 Arnaud Scherpereel, Hospital of the University of Lille, France

15:00 MS04.08: What Do We Know about Targeting Metabolism in Mesothelioma?
 Luciano Mutti, University of Salford, United Kingdom

13:45 - 15:15

MS05: Mini Symposium 05 - Drivers of Mesothelioma Initiation / Progression

Track: Basic Science

Chairs: Courtney Broaddus, United States & Licun Wu, Canada

Room: Provinces I - Level 4

13:45 MS05.01: Assessing the Carcinogenic Potential of Asbestos and Asbestiform Fibres in MexTAg Mice (Abstract ID: 630)
 Scott Fisher, National Centre for Asbestos Related Diseases (NCARD), Australia

13:55 MS05.02: Implication of ADAM10 Protease in Malignant Pleural Mesothelioma (Abstract ID: 519)
 Marine Bellefroid, University of Liege, Belgium

14:05 MS05.03: TAZ Activation by NF2-Hippo Pathway Dysregulation Induces Cytokine Expression and Provides Growth Advantage to Mesothelioma (Abstract ID: 580)
 Yoshitaka Sekido, Aichi Cancer Center Research Institute, Japan

14:15 MS05.04: Early Events during Asbestos-Driven Tumor Development (Abstract ID: 611)
 Emanuela Felley-Bosco, University Hospital Zürich, Switzerland

14:25 MS05.05: Evaluation of RAN Gene using siRNA and CRISPR/CAS9 in Malignant Pleural Mesothelioma (Abstract ID: 621)
 Irene Dell'Anno, University of Pisa, Italy

14:35 MS05.06: A Potential Therapeutic Strategy for Malignant Mesothelioma with Heparanase Inhibitors (Abstract ID: 673)
 Moshe Lapidot, Brigham and Women's Hospital, United States



14:45 MS05.07: Small Molecule Transcriptional Suppression of PRMT5 Induces Synthetic Lethality in MTAP-Negative Mesothelioma (Abstract ID: 734)

Sara Busacca, University of Leicester, United Kingdom

14:55 MS05.08: Depletion of M2 Mesothelioma-Associated Macrophages May Decrease Mesothelioma Cell Stemness Leading to Lessened Tumorigenesis (Abstract ID: 563)

Licun Wu, Toronto General Hospital and Princess Margaret Cancer Centre, Canada

15:05 MS05.09: Discussant

Steven Mutsaers, University of Western Australia, Australia

13:45 - 15:15

MS06: Mini Symposium 06 - Malignant Effusions

Track: Symptom Control / Palliative Care

Chairs: Fraser Brims, Australia & Dan Sterman, United States

Room: Provinces II - Level 4

13:45 MS06.01: Debate: What is the Optimal Approach to Manage Malignant Pleural Effusions?

Medical Management is Best

Nick Maskell, University of Bristol, United Kingdom

Surgical Management is Best

Marc De Perrot, Toronto General Hospital and Princess Margaret Cancer Center, Canada

14:15 MS06.02: The Prevalence of Pleural Effusions at Presentation: A Prospective Cohort of 229 Patients with Malignant Pleural Mesothelioma (Abstract ID: 549)

Anna Bibby, University of Bristol, United Kingdom

14:25 MS06.03: Is Pleural Infection Associated with Longer Survival in Mesothelioma? A Cohort Study Using Hospital Episode Statistics Data (Abstract ID: 757)

Anna Bibby, University of Bristol, United Kingdom

14:35 MS06.04: Catheter Tract Metastasis in Mesothelioma Patients with Indwelling Pleural Catheters (Abstract ID: 833)

Michael Mitchell, The Ottawa Hospital, Canada

14:45 **MS06.05: Diagnostic Value of Pleural Effusion Tumor Markers for Malignant Pleural Mesothelioma (Abstract ID: 751)**
Yasuhiro Hida, Hokkaido University Hospital, Japan

14:55 **MS06.06: Question & Answer Period**

15:15 - 16:00 **Poster Viewing with Coffee**
Room: Confederation II/III - Level 4

16:00 - 17:30 **PL02: Plenary Session 02 - Immunotherapy of Mesothelioma**
Track: Medical Oncology
Chairs: Scott Laurie, Canada & Jeremy Steele, United Kingdom
Room: Confederation I - Level 4

16:00 **PL02.01: Characterization of PD-L1 Protein Expression in a Large Cohort of Malignant Pleural Mesothelioma (Abstract ID: 699)**
Assunta De Rienzo, Brigham and Women's Hospital, United States

16:10 **PL02.02: Pathological Predictors of Response to Immunotherapy in MPM**
Françoise Galateau-Sallé, Centre Léon Bérard, France

16:25 **PL02.03: Second- or Third-Line Nivolumab vs. Nivo + Ipilimumab in Mesothelioma: Final Results of IFCT-1501 MAPS2 Randomized Phase 2 Trial (Abstract ID: 540)**
Arnaud Scherpereel, Hospital of the University of Lille, France

16:35 **PL02.04: Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma: Final Results of a Phase II Study (INITIATE) (Abstract ID: 669)**
Paul Baas, Netherlands Cancer Institute, Netherlands

16:45 **PL02.05: DREAM: A Phase 2 Trial of DuRvalumab with First-Line chemotherapy in Mesothelioma with a Safety Lead-In (Abstract ID: 536)**
Anna Nowak, University of Western Australia, Australia

16:55 **PL02.06: Real-World Outcomes for Patients Treated with Pembrolizumab (Pembro) for Relapsed Malignant Pleural Mesothelioma (MPM) (Abstract ID: 796)**
Kenneth O'Byrne, Queensland University of Technology, Australia



17:05 **PL02.07: Discussion: The Evolving Landscape of Immunotherapy
Trials for Mesothelioma**
Arnaud Scherpereel, Hospital of the University of Lille, France

17:20 **PL02.08: Question & Answer Period**

17:30 - 18:30 **Poster Mixer with Poster Discussions**
Room: Confederation II/III - Level 4



Friday, May 4, 2018

- 08:45 - 10:15** **PL03: Plenary Session 03 - Asbestos Control Perspectives: Before the Ban, the Ban, after the Ban**
 Track: Patient Advocacy
 Chairs: Paul Wheatley-Price, Canada & Sam Armato, United States
 Room: Confederation I - Level 4
- 08:45** **PL03.01: Surviving and Dying with Canadian Asbestos Hidden in Our Lungs. A Belgian World Activist Speaks Out**
 Eric Jonckheere, Belgian Asbestos Victims' Association, Belgium
- 09:00** **PL03.02: Advocating for a Ban in Emerging Economies: The Colombian Experience**
 Guillermo Villamizar, Fundclas, Colombia
- 09:15** **PL03.03: After the Asbestos Ban - the Australian Experience**
 Peter Tighe, Australian Asbestos Safety and Eradication Agency, Australia
- 09:30** **PL03.04: It Really Does Matter: Encouraging Workers Diagnosed with Mesothelioma to Apply for Compensation Just Makes Sense (Abstract ID: 819)**
 Liane Murphy, The Ottawa Hospital, Canada
- 09:40** **PL03.05: How We Achieved an Asbestos Ban in Canada - and Where We Need to Go from Here (Abstract ID: 777)**
 Alec Farquhar, Ontario Office of the Worker Adviser, Canada
- 09:50** **PL03.06: Implementing a Ban**
 Bob Blakely, Canada's Building Trades Unions, Canada
- 10:05** **PL03.07: Question & Answer Period**
- 10:15 - 11:00** **Poster Viewing with Coffee**
 Room: Confederation II/III - Level 4



11:00 - 12:30

MS07: Mini Symposium 07 - Translating Clinical Knowledge into Clinical Action

Track: Nursing

Chairs: Anastasia Bykova, Canada & Liz Darlison, United Kingdom

Room: Confederation I - Level 4

- 11:00 **MS07.01: Medical Oncology Treatment Modalities and Case Study**
 Buerkley Rose, University of Chicago, United States
- 11:15 **MS07.02: Radiation Oncology Treatment Modalities and Case Study**
 Erica Glass, Maryland Proton Treatment Center, United States
- 11:30 **MS07.03: Surgical Treatment Modalities and Case Study**
 Melissa Culligan, University of Maryland School of Medicine, United States
- 11:45 **MS07.04: Receiving a Diagnosis of MESOthelioma (RADIO Meso):
 Improving the Patient Experience**
(Abstract ID: 546 - Young Investigator Award Winner)
 Bethany Taylor, The University of Sheffield, United Kingdom
- 11:55 **MS07.05: A Collaborative Approach to a Successful Support Group
 for Mesothelioma Patients and Carers (Abstract ID: 718)**
 Lorraine Creech, Glenfield Hospital, United Kingdom
- 12:05 **MS07.06: National Lung Cancer Audit: Pleural Mesothelioma Report
 2016. The Influence of Mesothelioma UK Clinical Nurse Specialists
 (Abstract ID: 766)**
 Simon Bolton, Harrogate & District NHS Foundation Trust, United Kingdom
- 12:15 **MS07.07: Question & Answer Period**

11:00 - 12:30

MS08: Mini Symposium 08 - Radiation Oncology

Track: Radiation Oncology

Chairs: Robert MacRae, Canada & Andreas Rimner, United States

Room: Provinces I - Level 4

- 11:00 **MS08.01: SYSTEMS-2: A Phase II Randomised Study of Radiotherapy
 Dose Escalation for Pain Control in Malignant Pleural Mesothelioma
 (Abstract ID: 554)**
 Miranda Ashton, University of Glasgow, United Kingdom



- 11:10 MS08.02: Stereotactic Body Radiation Therapy as Salvage Therapy for Oligometastasised Pleural Mesothelioma after Multimodal Therapy (Abstract ID: 602)**
 Olivia Lauk, University Hospital Zürich, Switzerland
- 11:20 MS08.03: Radical/Salvage Approaches**
 Charles Simone, Maryland Proton Treatment Center, United States
- 11:35 MS08.04: Toxicities and Outcomes of Whole Pleural Intensity-Modulated Proton Therapy for Lung-Intact Malignant Pleural Mesothelioma (Abstract ID: 767)**
 Jason Molitoris, University of Maryland Medical Center, United States
- 11:45 MS08.05: An Investigation of Hybrid Planning with Multi Criteria Optimization for Mesothelioma (Abstract ID: 557)**
 Timothy Mitchell, Beatson West of Scotland Institute, United Kingdom
- 11:55 MS08.06: Understanding the Immune Response to Radiotherapy in a Dual Tumour Model of Mesothelioma (Abstract ID: 565)**
 Wesley Wilson, University of Western Australia, Australia
- 12:05 MS08.07: Palliative Radiation**
 Noelle O'Rourke, NHS Greater Glasgow and Clyde, United Kingdom
- 12:20 MS08.08: Question & Answer Period**

11:00 - 12:30

MS09: Mini Symposium 09 - Peritoneal Mesothelioma - Current Status

Track: Surgery

Chairs: Richard Alexander, United States & Kiran Turaga, United States

Room: Provinces II - Level 4

- 11:00 MS09.01: Updates in Peritoneal Mesothelioma**
 Richard Alexander, University of Maryland Medical Center, United States
- 11:15 MS09.02: Surgery for Peritoneal Recurrences and Management of Peritoneal Ascites**
 Kiran Turaga, University of Chicago, United States
- 11:30 MS09.03: Novel Systemic Therapy Approaches**
 Licun Wu, Toronto General Hospital and Princess Margaret Cancer Centre, Canada



- 11:45** **MS09.04: Early Outcomes from a Monthly International Peritoneal Mesothelioma Multi-Disciplinary Team Meeting in the UK and Ireland (Abstract ID: 747)**
 Andreas Brandl, Basingstoke and North Hampshire Hospitals, United Kingdom
- 11:55** **MS09.05: BAP1 Loss Predicts Therapeutic Vulnerability in Malignant Peritoneal Mesothelioma (Abstract ID: 684)**
 Raunak Shrestha, Vancouver Prostate Centre, Canada
- 12:05** **MS09.06: A Comprehensive Prognostic Model for Malignant Peritoneal Mesothelioma: Interim Analysis of an International Collaboration (Abstract ID: 594 - Young Investigator Award Winner)**
 David Chapel, University of Chicago, United States
- 12:15** **MS09.07: Question & Answer Period**

11:00 - 12:30

MS10: Mini Symposium 10 - Biomarkers of MPM: Inflammation, Antigens, T Cells and More

Track: Basic Science

Chairs: Jan van Meerbeeck, Belgium & Jenette Creaney, Australia

Room: Les Saisons - Level 3

- 11:00** **MS10.01: Serum miRNA Profiling of Malignant Pleural Mesothelioma and Early Diagnosis: A Massive Parallel Sequencing Approach (Abstract ID: 562 - Young Investigator Award Winner)**
 Elisabetta Casalone, Italian Institute for Genomic Medicine, Italy
- 11:10** **MS10.02: Preliminary Results of the Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) Study (Abstract ID: 620)**
 Kevin Blyth, Queen Elizabeth University Hospital, United Kingdom
- 11:20** **MS10.03: Experimental Model of Human Malignant Mesothelioma in Athymic Mice for in vivo Evaluation of Therapy Using MIF/CD74 Inhibitor (Abstract ID: 616)**
 Veronique Serre-Beinier, University Hospitals and Medical University of Geneva, Switzerland
- 11:30** **MS10.04: Time Course of Myeloid-Derived Suppressor Cells and M2 Macrophages in Murine Malignant Pleural Mesothelioma Microenvironment (Abstract ID: 590)**
 Mikihiro Kohno, Toronto General Research Institute, Canada



- 11:40 **MS10.05: Chrysotile-Induced Malignant Mesothelioma in Genetically Engineered Mouse Models (Abstract ID: 811)**
 Yuwaraj Kadariya, Fox Chase Cancer Center, United States
- 11:50 **MS10.06: Immunogenomic Determinants of Response to PD-1 Blockade in Malignant Pleural Mesothelioma (Abstract ID: 746)**
 Hyun-Sung Lee, Baylor College of Medicine, United States
- 12:00 **MS10.07: Phenotypic and Functional Analysis of Malignant Mesothelioma Tumor-Infiltrating Lymphocytes (TILs) (Abstract ID: 639)**
 Astero Klampatsa, University of Pennsylvania, United States
- 12:10 **MS10.08: Identification of the Molecular Signature of Intratumor Tregs and of Tumor-Derived Immunosuppressive Signals (Abstract ID: 606)**
 Stefano Biffo, Istituto Nazionale di Genetica Molecolare, Italy
- 12:20 **MS10.09: Question & Answer Period**

12:30 - 13:45

Lunch Break

Room: Confederation II/III - Level 4

13:45 - 15:15

MS11: Mini Symposium 11 - Advocacy and Screening

Track: Patient Advocacy

Chairs: Christopher Lee, Canada & Eudice Goldberg, Canada

Room: Confederation I - Level 4

- 13:45 **MS11.01: Mesothelioma Advocacy in the 21st Century (Abstract ID: 729)**
 Linda Reinstein, Asbestos Disease Awareness Organization, United States
- 13:55 **MS11.02: Meet the Experts: Evaluation of Speed Dating with Researchers on Action Mesothelioma Day in the UK (Abstract ID: 670)**
 Simon Bolton, Harrogate & District NHS Foundation Trust, United Kingdom
- 14:05 **MS11.03: Documentation of Asbestos Exposure in the Medical Records of Patients with Mesothelioma (Abstract ID: 523)**
 Christopher Lee, BC Cancer Agency, Canada



14:15 MS11.04: From Support to Social: The Evolution of the Papworth Mesothelioma Support Group (Abstract ID: 640)
 Kate Slaven, Papworth Hospital, United Kingdom

14:25 MS11.05: Discussant
 Paul Wheatley-Price, The University of Ottawa, Canada

Track: Screening

Chairs: Demetris Patsios, Canada & Sjaak Burgers, Netherlands

Room: Confederation I - Level 4

14:35 MS11.06: Screening for Malignant Pleural Mesothelioma and Early Lung Cancer in Asbestos-Exposed Individuals (Abstract ID: 768)
 Demetris Patsios, University Health Network, Canada

14:45 MS11.07: An Exhaled Breath Biopsy Earmarks Exclusive Screening for Malignant Pleural Mesothelioma (Abstract ID: 567)
 Kevin Lamote, University of Antwerp, Belgium

14:55 MS11.08: Headspace Analysis of Mesothelioma Cell Lines to Pinpoint in Vivo Breath Biomarkers (Abstract ID: 641)
 Kevin Lamote, University of Antwerp, Belgium

15:05 MS11.09: Discussant
 Jan van Meerbeeck, Ghent University Hospital, Belgium

13:45 - 15:15

MS12: Mini Symposium 12 - Radical Surgical Approaches

Track: Surgery

Chairs: Harvey Pass, United States & Donna Maziak, Canada

Room: Provinces I - Level 4

13:45 MS12.01: Progress in Surgical Procedures and Techniques
 Isabelle Opitz, University Hospital Zürich, Switzerland

14:00 MS12.02: The Relationship between Cancer Surgery, Lymph Nodes, Immunotherapy and T Cells (Abstract ID: 703)
 Jenette Creaney, University of Western Australia, Australia

14:10 MS12.03: Efficacy of Neoadjuvant Chemotherapy Followed by Resection in Pleural Mesothelioma with Positive Cervical Mediastinoscopy (Abstract ID: 700)
 Sristi Sharma, University of Colorado, United States



- 14:20 MS12.04: Impact of Different Treatment Modalities on Survival in Malignant Pleural Mesothelioma: Results of Case Control Analysis (Abstract ID: 754)**
 Muzaffer Metintas, Eskisehir Osmangazi University, Turkey
- 14:30 MS12.05: Pleurectomy/Decortication and Intraoperative Intrapleural Hyperthermic Cisplatin Perfusion for Malignant Pleural Mesothelioma (Abstract ID: 582)**
 Kenichi Okubo, Tokyo Medical and Dental University, Japan
- 14:40 MS12.06: Pleurectomy/Decortication for Malignant Pleural Mesothelioma Patients: A French Single-Center Cohort (Abstract ID: 748)**
 François Montagne, Hospital of the University of Lille, France
- 14:50 MS12.07: Diode-Pumped Laser for Lung-Sparing Surgical Treatment of Malignant Pleural Mesothelioma: Initial Single-Center Experience (Abstract ID: 727)**
 Servet Bölükbas, Kliniken Essen-Mitte, Germany
- 15:00 MS12.08: Discussant**
 Loic Lang-Lazdunski, Lister Hospital, United Kingdom

13:45 - 15:15

MS13: Mini Symposium 13 - Immuno-Oncology PD-1 and Beyond

Track: Medical Oncology

Chairs: Arnaud Scherpereel, France & Quincy Chu, Canada

Room: Provinces II - Level 4

- 13:45 MS13.01: Overview of Early Trials / Data on Non-PD-1 Drugs**
 Anna Nowak, University of Western Australia, Australia
- 14:00 MS13.02: Overview of CAR-T Therapy for Meso**
 Andrew Haas, University of Pennsylvania Perelman School of Medicine, United States
- 14:15 MS13.03: Mesothelin-Targeted Immunotoxin LMB-100 Plus Anti-PD-1 Antibody in Syngeneic Mouse Model Expressing Human Mesothelin (Abstract ID: 763)**
 Raffit Hassan, National Cancer Institute, United States
- 14:25 MS13.04: Live-Attenuated, Listeria Monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy for Treatment of MPM (Abstract ID: 794)**
 Evan Alley, University of Pennsylvania, United States



- 14:35 MS13.05: Rearrangement-Related Peptides with Neoantigenic Potential in Malignant Pleural Mesothelioma (Abstract ID: 533)**
 Aaron Mansfield, Mayo Clinic, United States
- 14:45 MS13.06: Rational Therapeutic Modulation of the Tumor Microenvironment Sensitizes Cancers to Immune Checkpoint Blockade (Abstract ID: 558 - Young Investigator Award Winner)**
 Rachael Zemek, University of Western Australia, Australia
- 14:55 MS13.07: PD1 Checkpoint Blockade Overcomes Upregulation of Multiple Inhibitory Receptors (Abstract ID: 724)**
 Jordan Dozier, Memorial Sloan Kettering, United States
- 15:05 MS13.08: Question & Answer Period**

13:45 - 15:15

MS14: Mini Symposium 14 - The Roles of miRNA and BAP1

Track: Basic Science

Chairs: Michele Carbone, United States & Penelope Bradbury, Canada

Room: Les Saisons - Level 3

- 13:45 MS14.01: Elucidating BAP1-microRNA Regulatory Networks in Mesothelioma (Abstract ID: 544)**
 Judy Coulson, University of Liverpool, United Kingdom
- 13:55 MS14.02: Malignant Pleural Mesothelioma Tissue-Of-Origin Classifiers Developed from Novel miRNAs Sequences (Abstract ID: 576)**
 Victor Martinez, BC Cancer Agency, Canada
- 14:05 MS14.03: Role of miRNA in Mesothelioma Progression**
 Michaela Kirschner, University Hospital Zurich, Switzerland
- 14:20 MS14.04: Histopathological and Molecular Characterization of BAP1 in Malignant Pleural Mesothelioma (Abstract ID: 584)**
 Assunta De Rienzo, Brigham and Women's Hospital, United States
- 14:30 MS14.06: Discovering and Translating BAP1 Dependencies: Towards Precision Therapy of Mesothelioma (Abstract ID: 740)**
 Sarah Taylor, University of Liverpool, United Kingdom
- 14:40 MS14.07: How BAP1 Modulates Gene-Environment Interaction in Carcinogenesis and Renders Tumour Cells Resistant to Chemotherapy (Abstract ID: 674)**
 Michele Carbone, University of Hawaii Cancer Center, United States
- 14:50 MS14.08: Question & Answer Period**



15:15 - 16:00

Poster Viewing with Coffee

Room: Confederation II/III - Level 4

16:00 - 17:30

PL04: Plenary Session 04 - The Genome and Epigenetics of Mesothelioma

Track: Basic Science

Chairs: Marie-Claude Jaurand, France & Christina Addison, Canada

Room: Confederation I - Level 4

16:00

PL04.01: Molecular Heterogeneity of Mesothelioma

Jean Didier, INSERM, France

16:15

PL04.02: Integrative Molecular Characterization of Malignant Pleural Mesothelioma: Final Report of The Cancer Genome Atlas Malignant Pleural Mesothelioma Project

Marc Ladanyi, Memorial Sloan Kettering Cancer Center, United States

16:30

PL04.03: The MexTAG Collaborative Cross: Identifying the Genetic Basis of Mesothelioma. An Interim Report (Abstract ID: 627)

Scott Fisher, National Centre for Asbestos Related Diseases (NCARD), Australia

16:40

PL04.04: Both Long-Fibre Carbon Nanotubes and Asbestos Alter the Level of DNA Methylation in the Pleura of Exposed Mice (Abstract ID: 761)

Joaquin Zacarias-Cabeza, Medical Research Council (MRC), United Kingdom

16:50

PL04.05: Long-Fibre CNT and Asbestos Induce Pleural Mesothelioma: A Key Role for Epigenetic Mechanisms in Disease Development (Abstract ID: 826)

Marion MacFarlane, MRC Toxicology Unit, United Kingdom

17:00

PL04.06: Germline Mutations in DNA Repair Genes Predispose Asbestos-Exposed Patients to Malignant Pleural Mesothelioma (Abstract ID: 721)

Irma Dianzani, HUGEF Human Genetics Foundation, Italy

17:10

PL04.07: Question & Answer Period

17:15

PL04.08: Application of CGH in Mesothelioma and its Role in the Identification of New Treatment Targets

Michele Carbone, University of Hawaii Cancer Center, United States

17:30 - 18:30

Poster Mixer with Poster Discussions

Room: Confederation II/III - Level 4



Saturday, May 5, 2018

08:45 - 10:15

PL05: Plenary Session 05 - Multidisciplinary Management

Track: Surgery

Chairs: Paul Baas, Netherlands & Walter Weder, Switzerland

Room: Confederation I - Level 4

08:45 **PL05.01: The Role of Surgery in the Multidisciplinary Management of Mesothelioma in 2018**
 Harvey Pass, New York University, United States

09:00 **PL05.02: EORTC 1205: Randomized Phase II Study of Pleurectomy/Decortication Preceded or Followed by Chemotherapy in Early Stage MPM**
 (Abstract ID: 543 - *Young Investigator Award Winner*)
 Jo Raskin, Antwerp University Hospital, Belgium

09:10 **PL05.03: Does the Administration of Total Parenteral Nutrition Following Extended Pleurectomy Decortication Offer Any Benefit?**
 (Abstract ID: 663)
 Alan Dawson, Glenfield Hospital, United Kingdom

09:20 **PL05.04: Quality of Life is Not Deteriorated After (Extended) Pleurectomy/Decortication vs. Pneumonectomy in Mesothelioma Patients (Abstract ID: 589)**
 Olivia Lauk, University Hospital Zürich, Switzerland

09:30 **PL05.05: Debate: When is the Best Time to Administer RT?**

Pre-Op

John Cho, University Health Network, Canada

Post-Op

Andreas Rimner, Memorial Sloan Kettering, United States

09:55 **PL05.06: Outcomes for Patients Treated with Surgery for Mesothelioma After Radiation Therapy: SMART Study Interim Results (Abstract ID: 660)**
 John Cho, University Health Network, Canada

10:05 **PL05.07: Question & Answer Period**

10:15 - 11:00

Poster Viewing with Coffee

Room: Confederation II/III - Level 4



11:00 - 12:30

MS15: Mini Symposium 15 - Surgical Palliation

Track: Surgery

Chairs: Joe Friedberg, United States & Marc De Perrot, Canada

Room: Confederation I - Level 4

- 11:00** **MS15.01: Diagnosis & Management of Local Recurrence**
Raphael Bueno, Brigham and Women's Hospital, United States
- 11:15** **MS15.02: Is There a Role for Purely Palliative Surgery?**
David Waller, St. Bartholomew Hospital, United Kingdom
- 11:30** **MS15.03: Surgical Management of Malignant Pleural Mesothelioma After Induction Chemotherapy: 18 Years of Single Center Experience (Abstract ID: 592)**
Olivia Lauk, University Hospital Zürich, Switzerland
- 11:40** **MS15.04: Pleurectomy/Decortication, Intrapleural Betadine, Prophylactic Radiotherapy and Systemic Chemotherapy: Long-Term Results (Abstract ID: 706)**
Loic Lang-Lazdunski, BUPA Cromwell Hospital, United Kingdom
- 11:50** **MS15.05: The Transition of Quality of Life After Pleurectomy/Decortication for Malignant Pleural Mesothelioma (Abstract ID: 717)**
Toru Nakamichi, Hyogo College of Medicine, Japan
- 12:00** **MS15.06: The Improving Results of Trimodality Treatment Strategy for Operable Malignant Pleural Mesothelioma (Abstract ID: 552)**
Kazunori Okabe, Yamaguchi Ube Medical Center, Japan
- 12:10** **MS15.07: Feasibility of Intrapleural PDT Combined with Pleurectomy/Decortication Then Chemotherapy in Malignant Pleural Mesothelioma (Abstract ID: 593)**
Arnaud Scherpereel, Hospital of the University of Lille, France
- 12:20** **MS15.08: Question & Answer Period**

11:00 - 12:30

MS16: Mini Symposium 16 - Interdisciplinary Symptom Control in MPM

Track: Symptom Control / Palliative Care

Chairs: Monica Malec, United States & Camille Munro, Canada

Room: Provinces I - Level 4

- 11:00** **MS16.01: Psychological Aspects of Management Dyspnea**
Amy Siston, University of Chicago, United States



- 11:15 MS16.02: Case-Based Complex Pain Issues in MPM**
 Monica Malec, University of Chicago, United States
- 11:30 MS16.03: A Multicentre RCT Assessing Regular Early Specialist Palliative Care in Malignant Pleural Mesothelioma: RESPECT-MESO (Abstract ID: 676)**
 Fraser Brims, Sir Charles Gairdner Hospital, Australia
- 11:40 MS16.04: MesoTRAP: A Feasibility Study Comparing VAT Pleurectomy with IPC for Trapped Lung in Pleural Mesothelioma (Abstract ID: 713)**
 Robert Rintoul, University of Cambridge, United Kingdom
- 11:50 MS16.05: MARS 2 Qualitative Assessment Study: Implications of Findings for Post-Surgical Follow-Up Care (Abstract ID: 638)**
 Angela Tod, The University of Sheffield, United Kingdom
- 12:00 MS16.06: A UK General Hospital's Experience with Malignant Pleural Mesothelioma in a High-Incidence Area (Abstract ID: 601)**
 Lewis Standing, Northumbria Healthcare Trust, United Kingdom
- 12:10 MS16.07: Question & Answer Period**

11:00 - 12:30

MS17: Mini Symposium 17 - Benign vs. Malignant Mesothelial Proliferations and Subtypes of MPM

Track: Pathology

Chairs: Andrew Churg, Canada & Françoise Galateau-Sallé, France

Room: Provinces II - Level 4

- 11:00 MS17.01: A Multi-Institutional Evaluation of Pleural Biphasic Mesothelioma by the International Mesothelioma Panel: New Insights (Abstract ID: 774)**
 Françoise Galateau-Sallé, Centre Leon Berard, France
- 11:10 MS17.02: New Data of the Molecular Subtypes of Mesothelioma**
 Lynnette Fernandez-Cuesta, International Agency for Research on Cancer, France
- 11:25 MS17.03: Differential Diagnosis of Malignant Pleural Mesothelioma: Effectiveness of a Gene Expression Panel on Pleural Effusions (Abstract ID: 607)**
 Rossella Bruno, University of Pisa, Italy



- 11:35 MS17.04: Image-Guided Percutaneous Pleural Biopsy Diagnostic Yield and Accuracy for Benign and Malignant Pleural Lesions (Abstract ID: 831)**
 Joao Inacio, The University of Ottawa, Canada
- 11:45 MS17.05: Immunohistochemical Detection of MTAP or BAP1 Protein Loss in Tissues and Cell Blocks for Diagnosis of Mesothelioma (Abstract ID: 709)**
 Kazuki Nabeshima, Fukuoka University School of Medicine, Japan
- 11:55 MS17.06: Gene Expression Profiling vs. p16 and BAP1 Evaluation in the Differential Diagnosis of Mesothelial Proliferations (Abstract ID: 609)**
 Greta Alì, Azienda Ospedaliero Universitaria, Italy
- 12:05 MS17.07: Correlation Between Benign and Malignant Mesothelial Proliferation**
 Andrew Churg, Vancouver General Hospital, Canada
- 12:20 MS17.08: Question & Answer Period**

12:30 - 14:00

Lunch Break

Room: Confederation II/III - Level 4

14:00 - 15:30

PL06: Plenary Session 06 - Immunotherapy, Bench to Bedside

Track: Basic Science

Chairs: Penelope Bradbury, Canada & Luciano Mutti, United Kingdom

Room: Confederation I - Level 4

- 14:00 PL06.01: How Recent Insights into the Immune Environment in Mesothelioma are Informing the Next Generation of Immunotherapies**
 Jenette Creaney, University of Western Australia, Australia
- 14:15 PL06.02: Epigenetics for Immunotherapy: Application to Mesothelioma**
 Christophe Blanquart, CRCINA, France
- 14:30 PL06.03: Neoantigen Abundance and MHC Protein Expression Underlie Immunogenicity in Malignant Pleural Mesothelioma (Abstract ID: 785)**
 Hyun-Sung Lee, Baylor College of Medicine, United States



- 14:40** **PL06.04: A Modified Measles Virus Exhibits Enhanced Oncolytic and Immunotherapeutic Properties Against Human Mesothelioma Cells (Abstract ID: 651)**
Nicolas Boisgerault, CRCINA Cancer Research Center, France
- 14:50** **PL06.05: Genetic Blockade of the Protein Tyrosine Phosphatase SHP1 Augments CAR T-Cell Activity against PDL1-Expressing Solid Tumors (Abstract ID: 526)**
Edmund Moon, University of Pennsylvania Perelman School of Medicine, United States
- 15:00** **PL06.06: Immune Profiling Identifies Differential Expression of Complement Pathway Genes Related to Molecular Clusters of Mesothelioma (Abstract ID: 586)**
David Severson, Brigham and Women's Hospital, United States
- 15:10** **PL06.07: Diagnostic and Prognostic Evaluation of M-CSF and IL-34 Cytokines in Pleural Effusions from Mesothelioma Patients (Abstract ID: 613)**
Thibaut Blondy, CRCINA, France
- 15:20** **PL06.08: Question & Answer Period**

15:30 - 16:00

Closing Remarks

Room: Confederation I - Level 4